Penumbra is set to report its fourth-quarter earnings, which could be its last as an independent entity before its acquisition by Boston Scientific. Analysts anticipate Penumbra to announce earnings of $1.10 per share on revenue of $361.8 million, building on its strong Q3 performance. The key focus for investors will be whether Penumbra’s revenue growth justifies Boston Scientific’s $14.5 billion acquisition and the performance of its middle meningeal artery embolization business.
Penumbra earnings on deck as Boston Scientific deal looms By Investing.com
Penumbra is set to report its fourth-quarter earnings, which could be its last as an independent entity before its acquisition by Boston Scientific. Analysts anticipate Penumbra to announce earnings of $1.10 per share on revenue of $361.8 million, building on its strong Q3 performance. The key focus for investors will be whether Penumbra’s revenue growth justifies Boston Scientific’s $14.5 billion acquisition and the performance of its middle meningeal artery embolization business.